These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 11504817)

  • 1. Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury.
    Yu JC; Lokker NA; Hollenbach S; Apatira M; Li J; Betz A; Sedlock D; Oda S; Nomoto Y; Matsuno K; Ide S; Tsukuda E; Giese NA
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1172-8. PubMed ID: 11504817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
    Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
    Lokker NA; Sullivan CM; Hollenbach SJ; Israel MA; Giese NA
    Cancer Res; 2002 Jul; 62(13):3729-35. PubMed ID: 12097282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of red and white wines on inhibition of the platelet-derived growth factor receptor: impact of the mash fermentation.
    Sparwel J; Vantler M; Caglayan E; Kappert K; Fries JW; Dietrich H; Böhm M; Erdmann E; Rosenkranz S
    Cardiovasc Res; 2009 Mar; 81(4):758-70. PubMed ID: 19074160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo.
    Hacker TA; Griffin MO; Guttormsen B; Stoker S; Wolff MR
    J Invasive Cardiol; 2007 Jun; 19(6):269-74. PubMed ID: 17541129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delphinidin, a dietary anthocyanidin, inhibits platelet-derived growth factor ligand/receptor (PDGF/PDGFR) signaling.
    Lamy S; Beaulieu E; Labbé D; Bédard V; Moghrabi A; Barrette S; Gingras D; Béliveau R
    Carcinogenesis; 2008 May; 29(5):1033-41. PubMed ID: 18339683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effect of magnesium lithospermate B on neointimal formation after balloon-induced vascular injury.
    Hur KY; Seo HJ; Kang ES; Kim SH; Song S; Kim EH; Lim S; Choi C; Heo JH; Hwang KC; Ahn CW; Cha BS; Jung M; Lee HC
    Eur J Pharmacol; 2008 May; 586(1-3):226-33. PubMed ID: 18387604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of vascular smooth muscle cell proliferation and intimal thickening after balloon injury by the sulfated oligosaccharide PI-88: phosphomannopentaose sulfate directly binds FGF-2, blocks cellular signaling, and inhibits proliferation.
    Francis DJ; Parish CR; McGarry M; Santiago FS; Lowe HC; Brown KJ; Bingley JA; Hayward IP; Cowden WB; Campbell JH; Campbell GR; Chesterman CN; Khachigian LM
    Circ Res; 2003 May; 92(8):e70-7. PubMed ID: 12690039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
    Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
    Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 3. Replacement of quinazoline moiety and improvement of metabolic polymorphism of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.
    Matsuno K; Ushiki J; Seishi T; Ichimura M; Giese NA; Yu JC; Takahashi S; Oda S; Nomoto Y
    J Med Chem; 2003 Nov; 46(23):4910-25. PubMed ID: 14584942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antioxidants relieve phosphatase inhibition and reduce PDGF signaling in cultured VSMCs and in restenosis.
    Kappert K; Sparwel J; Sandin A; Seiler A; Siebolts U; Leppänen O; Rosenkranz S; Ostman A
    Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2644-51. PubMed ID: 16990553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability.
    Patel N; Sun L; Moshinsky D; Chen H; Leahy KM; Le P; Moss KG; Wang X; Rice A; Tam D; Laird AD; Yu X; Zhang Q; Tang C; McMahon G; Howlett A
    J Pharmacol Exp Ther; 2003 Sep; 306(3):838-45. PubMed ID: 12766257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of platelet-derived growth factor signaling in healing myocardial infarcts.
    Zymek P; Bujak M; Chatila K; Cieslak A; Thakker G; Entman ML; Frangogiannis NG
    J Am Coll Cardiol; 2006 Dec; 48(11):2315-23. PubMed ID: 17161265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific inhibitor of FGF receptor signaling: FGF-2-mediated effects on proliferation, differentiation, and MAPK activation are inhibited by PD173074 in oligodendrocyte-lineage cells.
    Bansal R; Magge S; Winkler S
    J Neurosci Res; 2003 Nov; 74(4):486-93. PubMed ID: 14598292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of Kit inhibitors: suppression of Kit signaling and melanogenesis by emodin.
    Lee SJ; Jeong D; Park WK; Kong JY; Choi G; Kim H; Kang S; Cho H
    Phytother Res; 2010 Feb; 24(2):308-12. PubMed ID: 19585486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor beta-receptor (beta-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases.
    Zaman GJ; Vink PM; van den Doelen AA; Veeneman GH; Theunissen HJ
    Biochem Pharmacol; 1999 Jan; 57(1):57-64. PubMed ID: 9920285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of alpha and beta platelet-derived growth factor receptor in the vascular response to injury in nonhuman primates.
    Giese NA; Marijianowski MM; McCook O; Hancock A; Ramakrishnan V; Fretto LJ; Chen C; Kelly AB; Koziol JA; Wilcox JN; Hanson SR
    Arterioscler Thromb Vasc Biol; 1999 Apr; 19(4):900-9. PubMed ID: 10195916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Crataegus extract WS 1442 inhibits balloon catheter-induced intimal hyperplasia in the rat carotid artery by directly influencing PDGFR-beta.
    Fürst R; Zirrgiebel U; Totzke F; Zahler S; Vollmar AM; Koch E
    Atherosclerosis; 2010 Aug; 211(2):409-17. PubMed ID: 20435310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonism of platelet-derived growth factor by perivascular gene transfer attenuates adventitial cell migration after vascular injury: new tricks for old dogs?
    Mallawaarachchi CM; Weissberg PL; Siow RC
    FASEB J; 2006 Aug; 20(10):1686-8. PubMed ID: 16790526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.